Pharvaris N.V.
PHVS
Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor antagonists designed to address hereditary angioedema and related angioedema conditions through on-demand and preventive treatment options. Its current pipeline includes formulations intended for acute attack management as well as longer-acting prophylactic use, reflecting a portfolio built around differentiated oral approaches in a market still served by injectable and other traditional therapies. Pharvaris operates as a research-driven drug developer with activities spanning clinical development, regulatory engagement, and eventual commercialization of therapies for underserved patient populations. The company is headquartered in Zug, Switzerland.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€171M
▼ -30.9% YoY
Op. Margin
–
ROIC
-49.63%
▼ -14.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€155M
▼ -13.7% YoY
Op. Cash Flow (TTM)
-€155M
▼ -14.1% YoY
Net Debt
-€291M
Net Cash Position
Cash & Equiv.
€292M
Continue Research
Peers
Biotechnology · Pick stocks to compare with PHVS
Held by ETFs
PHVS is in 16 US ETFs. The largest of them, with PHVS's weight in each:
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
iShares Biotechnology ETFIBB0.07%of the fund
iShares Core MSCI Europe ETFIEUR0.00%of the fund
iShares U.S. Small-Cap Equity Factor ETFSMLF0.01%of the fund
iShares MSCI Netherlands ETFEWN0.25%of the fund
iShares MSCI Europe Small-Cap ETFIEUS0.05%of the fund
Pharvaris (PHVS) in three numbers
Questions about Pharvaris
Is Pharvaris a high-quality business?
Pharvaris scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$291M, and its weakest is return on capital at -49.6%. The Quality tab shows every check against its target.
Does Pharvaris (PHVS) pay a dividend?
No. Pharvaris (PHVS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PHVS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.